Startups
Immunic
New York, New York, United States · Gräfelfing, Bavaria, Germany
Biotechnology company developing oral small molecule treatments for neurological and autoimmune diseases. Its lead candidate, vidofludimus calcium, combines Nurr1 activation with DHODH inhibition and is being studied in Phase 3 trials for relapsing multiple sclerosis. Earlier programs include IMU-381 and IMU-856. The company also invests in enterprise data, analytics and AI capabilities to support clinical development and potential commercialization.
Founded 2016
Team
 Barclay PhillipsIndependent Director |
 Chitrang DavéChief Data and Digital Officer |
 Elena RidloffIndependent Director |
 Erik LundgrenChief Executive Officer · Board Director |
 Glenn WhaleyChief Financial Officer |
 Hella KohlhofCo-Founder and Chief Scientific Officer |
 Inderpal SinghGeneral Counsel |
 Jason TardioPresident and Chief Operating Officer |
 Jessica BreuVice President Investor Relations and Communications |
 Jon CongletonIndependent Director |
 Jörg NeermannIndependent Director |
 Michael A. PanzaraChief Medical Officer |
 Michael W. BonneyChair |
 Patrick WalshChief Business Officer |
 Richard RudickIndependent Director |
 Simona SkerjanecIndependent Director |
 Thor NagelDirector |
 Werner GladdinesChief Development Officer |